Factors predicting the progression of diabetic kidney disease in type 2 diabetic patients using continuous glucose monitoring

Main Article Content

K.I. Moshenets
N.O. Pertseva


Background. An increase in the prevalence of type 2 diabetes mellitus (DM) is accompanied by an increase in the number of patients with severe chronic complications. Diabetic kidney disease (DKD) is the leading cause of death in these patients after cardiovascular diseases. The purpose was to predict the progression of DKD in patients with type 2 diabetes mellitus depending on the glucose variability (GV) measured by continuous glucose monito­ring. Materials and methods. We examined 53 type 2 DM patients aged 57.0 (51.0; 64.0) years with an average disease duration of 9.0 (6.0; 13.0) years. The laboratory examination included determination of glycated hemoglobin, blood creatinine, albuminuria (AU), glomerular filtration rate (GFR) according to CKD-EPI equation. GV was measured by iPro2 GMS system. The maximum and minimum blood glucose levels and standard deviation (SD) of glycemia were considered. The role of GV in predicting DKD progression has been established using stepwise multiple regression analysis. Results. DKD was detected in 41.51 % of patients. In regression analysis, we created a linear multiple regression equation to describe the dependence of AU on the GV, F = 10.39 (p < 0.001). The variability of AU by 36.7 % is due to the minimum level of glycemia and SD of glycemia — multiple correlation coefficient R is 0.6372, the coefficient of determination R2 is 0.4060, adjusted R2 is 0.3670. Partial coefficient of correlation between AU and SD of glycemia, r = 0.25 (p = 0.027); between AU and the minimum blood glucose level, r = 0.31 (p = 0.005). Conclusions. According to the results of correlation analysis, a significant effect of GV, as well as the value of minimum blood glucose level on AU was established. It is statistically proved that high fluctuations of glycemia (SD) should be considered as a factor predicting the progression of DKD in type 2 DM patients. Using regression analysis, a mathematical model of DKD progression in type 2 DM patients was developed based on GV parameters.

Article Details

How to Cite
Moshenets, K., and N. Pertseva. “Factors Predicting the Progression of Diabetic Kidney Disease in Type 2 Diabetic Patients Using Continuous Glucose Monitoring”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 7, Jan. 2022, pp. 552-6, doi:10.22141/2224-0721.17.7.2021.244970.
Original Researches


Sagoo MK, Gnudi L. Diabetic Nephropathy: An Overview. Methods Mol Biol. 2020;2067:3-7. doi: 10.1007/978-1-4939-9841-8_1.

A/L B Vasanth Rao VR, Tan SH, Candasamy M, Bhattamisra SK. Diabetic nephropathy: An update on pathogenesis and drug development. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):754-762. doi: 10.1016/j.dsx.2018.11.054.

Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, Chrousos GP, Papassotiriou I. Biomarkers of diabetic nephropathy: A 2017 update. Crit Rev Clin Lab Sci. 2017 Aug;54(5):326-342. doi: 10.1080/10408363.2017.1377682.

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151.

Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 Sep 8;370(9590):829-40. doi: 10.1016/S0140-6736(07)61303-8.

King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999 Nov;48(5):643-8. doi: 10.1046/j.1365-2125.1999.00092.x.

American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33. doi: 10.2337/dc21-S002.

Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019 Feb 19;8(4):e011295. doi: 10.1161/JAHA.118.011295.

Lin YH, Huang YY, Chen HY, et al. Impact of Carbohydrate on Glucose Variability in Patients with Type 1 Diabetes Assessed Through Professional Continuous Glucose Monitoring: A Retrospective Study. Diabetes Ther. 2019 Dec;10(6):2289-2304. doi: 10.1007/s13300-019-00707-x.

Koval SM, Yushko KO, Snihurska IO, et al. Relations of angiotensin-(1-7) with hemodynamic and cardiac structural and functional parameters in patients with hypertension and type 2 diabetes. Arterial Hypertension (Poland). 2019;23(3):183-189. doi: 10.5603/AH.a2019.0012.

Sakamoto M. Type 2 diabetes and glycemic variability: various parameters in clinical practice. J Clin Med Res. 2018;10(10):737‐42. doi: 10.14740/jocmr3556w.

Ministry of Health of Ukraine. Order No 1118 from Nov 12, 2012. The unified clinical protocols of primary and secondary (specialized) medical care: Type 2 diabetes mellitus. Kyiv; 2012. 115 p. (in Ukrainian).

Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.

Taub PJ, Westheimer E. Biostatistics. Plast Reconstr Surg. 2009 Aug;124(2):200e-208e. doi: 10.1097/PRS.0b013e3181addcd9.

Rodbard D. Glucose Variability: A Review of Clinical Applications and Research Developments. Diabetes Technol Ther. 2018 Jun;20(S2):S25-S215. doi: 10.1089/dia.2018.0092.

Viazzi F, Russo GT, Ceriello A, et al. Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. J Nephrol. 2019 Aug;32(4):517-525. doi: 10.1007/s40620-018-00561-3.

Subramanian S, Hirsch IB. Diabetic Kidney Disease: Is There a Role for Glycemic Variability? Curr Diab Rep. 2018 Feb 15;18(3):13. doi: 10.1007/s11892-018-0979-3.

Hissa MRN, Hissa PNG, Guimarães SB, Hissa MN. Use of continuous glucose monitoring system in patients with type 2 mellitus diabetic during hemodialysis treatment. Diabetol Metab Syndr. 2021 Oct 9;13(1):104. doi: 10.1186/s13098-021-00722-8.

Ceriello A, De Cosmo S, Rossi MC, et al. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab. 2017 Nov;19(11):1570-1578. doi: 10.1111/dom.12976.

Yeoh E, Lim BK, Fun S, et al. Efficacy of self-monitoring of blood glucose versus retrospective continuous glucose monitoring in improving glycaemic control in diabetic kidney disease patients. Nephrology (Carlton). 2018 Mar;23(3):264-268. doi: 10.1111/nep.12978.

Tsaryk IO, Pashkovska NV. Peculiarities of the course of diabetic kidney disease in patients with latent autoimmune diabetes in adults. International Journal of Endocrinology (Ukraine). 2021;17(2):116-120. doi: 10.22141/2224-0721.17.2.2021.230565.

Chan CL, Pyle L, Kelsey MM, et al. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes. Pediatr Diabetes. 2017 Nov;18(7):629-636. doi: 10.1111/pedi.12475.

Breyton AE, Lambert-Porcheron S, Laville M, Vinoy S, Nazare JA. CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review. Front Endocrinol (Lausanne). 2021 Sep 9;12:666008. doi: 10.3389/fendo.2021.666008.

Most read articles by the same author(s)